Life Tech Inks Supply Deal with Novartis for Dynabeads | GenomeWeb

NEW YORK (GenomeWeb News) – Life Technologies today said that it has signed an agreement to supply Novartis with its Dynabeads for use in immunotherapeutics being developed by the drug firm for cancer.

The agreement includes a license to Life Tech's intellectual property to perform the resulting therapy and it is exclusive for use in the field of chimeric antigen receptors for the treatment of cancer. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.